FDA grants priority review to Novartis’ Sembrix for newly diagnosed patients with chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia

Results from the ASC4FIRST study led to the FDA granting Priority Review designation to Scemblix for newly diagnosed patients with chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia.